Frontline Pembrolizumab Improves PFS, OS in HER2- Gastric/GEJ Cancers
Adding pembrolizumab to frontline chemotherapy improves outcomes in patients with HER2-negative, advanced gastric or GEJ cancers, a phase 3 trial suggests.
Adding pembrolizumab to frontline chemotherapy improves outcomes in patients with HER2-negative, advanced gastric or GEJ cancers, a phase 3 trial suggests.
Timely discussions about end-of-life preferences can ensure patients with advanced cancer receive care that aligns with their goals, experts say.
Implementation of precision oncology recommendations has clinical utility for patients with gastrointestinal cancers.
Researchers explored the potential relationship between bariatric surgery for severe obesity and risk of esophageal and gastric cancers.
Researchers sought to determine which of 4 well-known prognostic scoring systems were more accurate in patients with advanced GE cancer.
The 5-year cumulative incidence of cancer-specific mortality was lower with trimodality therapy than with definitive chemoradiation in patients with adenocarcinoma and squamous cell carcinoma.
A chemotherapy-containing regimen appears more effective than a chemotherapy-free regimen as first-line therapy for ERBB2-positive gastric cancer.
For patients with stage II/III esophageal cancer, five-year survival is improved with early versus delayed esophagectomy.
The incidence of esophageal cancer nearly doubled, and this was not due to an increase in screening.
Tislelizumab reduced the risk of death by 30%, when compared with chemotherapy.